ClinicalTrials.gg
TerminatedNCT06053684Updated Nov 13, 2026

Non-Invasive Ventilation Versus Neurally-Adjusted Ventilatory Assistance (NAVA) for the Treatment of Bronchiolitis

An interventional study of Standard Non-Invasive Mechanical Servo Ventilation and Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation in Bronchiolitis, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 0 Years to 2 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Treatment

Why this study was terminated
Challenges associated with accrual of the eligible patient population.

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.
Updated Nov 13, 2026Now TerminatedNow Suspended+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
0 Years to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Bronchiolitis with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Bronchiolitis · United States.

Enrollment
41st of 49
20 · median 72
Started
2023
with 2 others
No phase
33 of 65
1 open now
Registered
60th of 65
by date
Lead sponsor
2 of 65
Montefiore Medical Center

Among the 65 studies in Bronchiolitis with a site in United States, this one is the 41st largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2023, is one of 33 with no phase, and was the 60th registered.

Bronchiolitis

289 studies on the registry are indexed under Bronchiolitis; 51 are open to participants now.

Browse Bronchiolitis studies →

Open to participants now

4 of the 65 studies in Bronchiolitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Bronchiolitis studies recruiting now, 4 (15%) set no upper age limit and 21 (81%) stop at 75 or younger; 23 take children under 18; none take healthy volunteers.

This study: 0 Years to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiolitis with a site in United States, or all of them as a file.
02

Study summary

This project aims to answer whether the use of a Neurally-Adjusted Ventilatory Assistance mode for non-invasive ventilation in pediatric patients with bronchiolitis results in improved comfort and reduced escalations in therapy (including intubation) when compared to using a standard mode of non-invasive ventilation. Neurally-Adjusted Ventilatory Assistance (NAVA) has been shown to result in greater synchrony then the standard mode of non-invasive ventilation. The study team hypothesizes that this improved synchrony can result in important clinical improvements when NAVA is used to treat children with bronchiolitis.

Read the detailed description

Bronchiolitis is a common diagnosis in pediatric hospitals and critical care units. Viral infection in younger patients often results in increased work of breathing, hypoxemia, impaired ventilation, and increased secretion burden. In some cases, treatment of severe respiratory failure includes intubation and mechanical ventilation. Current practice for patients with bronchiolitis who require hospital admission is to initially provide non-invasive ventilation to improve the patient's respiratory mechanics. This non-invasive respiratory support can range from simple nasal cannula, to high-flow nasal cannula, to non-invasive positive pressure ventilation.

The high-flow nasal cannula (HFNC) provides warm, humidified, oxygen-enriched air. Therapy commonly is prescribed with a prescribed fraction of inhaled oxygen (FiO2) delivered at 1-2 L/kg/min. This helps to improve oxygenation as the high rate of flow can "wash-out" carbon dioxide in the upper airways and thus reduce the volume of dead space ventilation.

Non-invasive ventilation (NIV) essentially provides a similar method of support as invasive ventilation without the use of endotracheal tube. Prescribed airway support is instead delivered non-invasively through a specialized nasal cannula or for larger children an occlusive facemask of appropriate size. The ventilator provides positive-end expiratory pressure (PEEP) with a prescribed delivery rate of a set inspiratory pressure (positive inspiratory pressure, or pressure control). This ventilator support enables the delivery of a set FiO2, helps maintain open airways to reduce atelectasis and allow for improved oxygenation with better V/Q matching, and improves work of breathing. The ventilator analyzes the flow generated by the patient's inspiratory effort and attempts to provide the prescribed positive inspiratory pressure at the time of the patient's own effort.

One of the major drawbacks of non-invasive ventilation for young pediatric patients with bronchiolitis is the difficulty in achieving synchrony between patient effort and ventilator-delivered positive inspiratory pressure. This is secondary to the large air leak given the non-invasive apparatus and the low inspiratory flows generated by this patient population. Thus, the ventilator and patient are often dyssynchronous which may actually increase work of breathing and agitation while impeding on the ventilatory support provided.

Neurally-Adjusted Ventilatory Assistance (NAVA) attempts to mitigate the harms of ventilator/patient dyssynchrony. This modality utilizes a specialized catheter placed into the esophagus, often via a nasogastric route, which has the capability of monitoring the electrical activity of the patient's diaphragm. This catheter can also be utilized to deliver feeds similarly to a basic nasogastric tube. The NAVA catheter monitors both the activation of the patient's diaphragm (indicating patient respiratory effort) and the strength of this activation in, referred to as the electrical activity of the diaphragm (Edi) and measured in millivolts (µV). Both human and animal studies have positively correlated the peak Edi values with work-of-breathing and demonstrated higher Edi values when respiratory pathology is present . Based on the Edi tracing, the ventilator can then deliver positive inspiratory pressure that is synchronous with both the patient's respiratory effort and proportional to the strength of this effort through a multiplier referred to as the NAVA level on the ventilator. This modality has been shown to improve patient agitation levels, reduce the need for sedating medications, and enhance synchrony in non-invasive ventilation modes.

The current practice model of the investigators entails that patients with bronchiolitis who require more than 1.5 L/kg of HFNC or require non-invasive ventilation, whether via a conventional or NAVA modality, are managed in the Pediatric Intensive Care Unit (PICU). Both modalities for non-invasive ventilation (conventional and NAVA) are used routinely. Patient respiratory status is aggregated into a value known as the Respiratory Severity Score (RSS) which accounts for respiratory rate, dyspnea, retractions, and auscultatory findings adjusted for the age of the patient. The RSS value is a validated assessment tool with good interobserver reliability between Medical Doctors (MDs), Registered Nurses (RNs), and Respiratory Therapists (RTs). It is calculated on a 4-hour basis for all patients with bronchiolitis in the investigator's PICU and helps determine clinical improvement or deterioration and better guide decisions to increase or decrease support.

While multiple physiologic studies demonstrate a reduced work of breathing with invasive NAVA ventilation, the majority of pediatric studies focused on non-invasive NAVA ventilation were designed to determine improvements in patient/ventilator synchronization. The investigators' project aims are two-fold. The study team hypothesizes that Edi levels and RSS scores will positively correlate for patients with bronchiolitis, allowing for another metric to gauge clinical status. The investigators also hypothesizes that the improved synchronization on NAVA-NIV may improve respiratory status as measured by RSS scores and Edi levels, reduce further escalations in respiratory support, shorten the length of non-invasive ventilation required, and reduce intubation rates. This improvement will be more substantial when transitioning from HFNC to NAVA-NIV compared to transitioning to conventional-NIV.

03

Conditions studied

  • Bronchiolitis

Browse trials for

04

Who can participate

Ages eligible
0 Years to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients under the age of two years old with a diagnosis of bronchiolitis presenting to the pediatric ICU
  • Patient's provider believes there is equipoise between the use of NAVA or conventional non-invasive ventilation for the patient

Exclusion criteria

Exclusion Criteria:

  • Patients unable to utilize a nasogastric tube
  • Patients with a diagnosis of chronic lung disease, cyanotic heart lesions, or congestive heart failure
  • Patients with hypotonia
  • Patients likely to require imminent intubation: >0.60 Fraction of Inspired Oxygen (FiO2); Carbon Dioxide (CO2) > 60, frequent apneas, clinician determines patient unlikely to tolerate non-invasive modality)
  • Patients with hemodynamic instability, defined as the need for vasoactive medication
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Standard Non-Invasive Mechanical Servo Ventilation Arm

    This arm will utilize a standard mode of non-invasive ventilation within protocol parameters.

    Device: Standard Non-Invasive Mechanical Servo Ventilation

  • Experimental
    Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation Arm

    This arm with utilize a NAVA mode of non-invasive ventilation within protocol parameters.

    Device: Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation

Interventions

  • DeviceStandard Non-Invasive Mechanical Servo Ventilation

    The active comparator arm will utilize a standard non-invasive mode to provide ventilation support

  • DeviceNeurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation

    The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support

06

What researchers measure

Primary outcomes

  1. Baseline Respiratory Severity Score (RSS)

    RSS is a validated measure of severity in children with bronchiolitis, scored from 0-12 with higher numbers indicating greater severity. If able, baseline scores will be taken before randomization to either treatment arm.

    Time frame: Approximately one hour after Edi catheter placement

  2. Average Respiratory Severity Score (RSS)

    RSS is a validated measure of severity in children with bronchiolitis, scored from 0-12 with higher numbers indicating greater severity. Average RSS values over a 48-hour period will be reported for each treatment arm.

    Time frame: 48 hour average, values collected at ~4 hour intervals.

  3. Baseline Electrical Activity of the Diaphragm (Edi)

    Measure, in microvolts, recorded by the Edi catheter to reflect activity of diaphragmatic activation. Higher values correspond with increased diaphragmatic activation. If able, will be collected prior to randomization to either treatment arm.

    Time frame: Approximately one hour after Edi catheter placement

  4. Average Baseline Electrical Activity of the Diaphragm (Edi)

    Measure, in microvolts, recorded by the Edi catheter to reflect activity of diaphragmatic activation. Higher values correspond with increased diaphragmatic activation. Average Edi values over a 48-hour period will be reported for each treatment arm.

    Time frame: 48 hour average, values collected at ~4 hour intervals.

Secondary outcomes

  1. Duration of Non-Invasive Ventilation

    The duration, in hours, that a patient requires non-invasive ventilation.

    Time frame: Time of randomization or start of non-invasive ventilation (whichever occurs last) up to 4 weeks later or time of intubation (whichever occurs first)

  2. Number of participants requiring intubation

    If a patient requires intubation due to bronchiolitis, this information will be recorded

    Time frame: Following start of non-invasive ventilation or randomization (whichever comes last) up to 4 weeks later

  3. Frequency of increasing ventilatory support

    The number of times that a physician increases respiratory support settings on the ventilator (other than FiO2) while remaining within protocol parameters will be documented. The number of events, limited to one event per hour, of increase in respiratory support will be counted during the study period. A greater number of increases in ventilatory support will indicate inadequate response to the treatment arm intervention.

    Time frame: From hours 4-48 of the intervention period

  4. Number of patients requiring dexmedetomidine

    The number of patients requiring dexmedetomidine will be tabulated. The use of dexmedetomidine use likely reflects patient agitation and inability to ventilate adequately on non-invasive ventilation. The use of dexmedetomidine may indicate more agitation present within a given treatment arm.

    Time frame: Through 48 hour study intervention period

07

Study locations

1 site
  • Children's Hospital at Montefiore
    The Bronx, New York 10467, United States
08

References and documents

Publications

  • Lodeserto FJ, Lettich TM, Rezaie SR. High-flow Nasal Cannula: Mechanisms of Action and Adult and Pediatric Indications. Cureus. 2018 Nov 26;10(11):e3639. doi: 10.7759/cureus.3639. PubMed 30740281 ↗
  • Javouhey E, Barats A, Richard N, Stamm D, Floret D. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis. Intensive Care Med. 2008 Sep;34(9):1608-14. doi: 10.1007/s00134-008-1150-4. Epub 2008 May 24. PubMed 18500424 ↗
  • Morley SL. Non-invasive ventilation in paediatric critical care. Paediatr Respir Rev. 2016 Sep;20:24-31. doi: 10.1016/j.prrv.2016.03.001. Epub 2016 Mar 14. PubMed 27118355 ↗
  • Jones ML, Bai S, Thurman TL, Holt SJ, Heulitt MJ, Courtney SE. Comparison of Work of Breathing Between Noninvasive Ventilation and Neurally Adjusted Ventilatory Assist in a Healthy and a Lung-Injured Piglet Model. Respir Care. 2018 Dec;63(12):1478-1484. doi: 10.4187/respcare.06192. Epub 2018 Sep 25. PubMed 30254048 ↗
  • Pham TM, O'Malley L, Mayfield S, Martin S, Schibler A. The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. Pediatr Pulmonol. 2015 Jul;50(7):713-20. doi: 10.1002/ppul.23060. Epub 2014 May 21. PubMed 24846750 ↗
  • Alander M, Peltoniemi O, Pokka T, Kontiokari T. Comparison of pressure-, flow-, and NAVA-triggering in pediatric and neonatal ventilatory care. Pediatr Pulmonol. 2012 Jan;47(1):76-83. doi: 10.1002/ppul.21519. Epub 2011 Aug 9. PubMed 21830318 ↗
  • Kallio M, Peltoniemi O, Anttila E, Pokka T, Kontiokari T. Neurally adjusted ventilatory assist (NAVA) in pediatric intensive care--a randomized controlled trial. Pediatr Pulmonol. 2015 Jan;50(1):55-62. doi: 10.1002/ppul.22995. Epub 2014 Jan 31. PubMed 24482284 ↗
  • Ducharme-Crevier L, Beck J, Essouri S, Jouvet P, Emeriaud G. Neurally adjusted ventilatory assist (NAVA) allows patient-ventilator synchrony during pediatric noninvasive ventilation: a crossover physiological study. Crit Care. 2015 Feb 17;19(1):44. doi: 10.1186/s13054-015-0770-7. PubMed 25886793 ↗
  • Liu LL, Gallaher MM, Davis RL, Rutter CM, Lewis TC, Marcuse EK. Use of a respiratory clinical score among different providers. Pediatr Pulmonol. 2004 Mar;37(3):243-8. doi: 10.1002/ppul.10425. PubMed 14966818 ↗
  • Duyndam A, Bol BS, Kroon A, Tibboel D, Ista E. Neurally adjusted ventilatory assist: assessing the comfort and feasibility of use in neonates and children. Nurs Crit Care. 2013 Mar-Apr;18(2):86-92. doi: 10.1111/j.1478-5153.2012.00541.x. Epub 2012 Nov 22. PubMed 23419184 ↗
  • Stein H, Hall R, Davis K, White DB. Electrical activity of the diaphragm (Edi) values and Edi catheter placement in non-ventilated preterm neonates. J Perinatol. 2013 Sep;33(9):707-11. doi: 10.1038/jp.2013.45. Epub 2013 May 2. PubMed 23636099 ↗
  • Beck J, Emeriaud G, Liu Y, Sinderby C. Neurally-adjusted ventilatory assist (NAVA) in children: a systematic review. Minerva Anestesiol. 2016 Aug;82(8):874-83. Epub 2015 Sep 16. PubMed 26375790 ↗
  • Vignaux L, Grazioli S, Piquilloud L, Bochaton N, Karam O, Levy-Jamet Y, Jaecklin T, Tourneux P, Jolliet P, Rimensberger PC. Patient-ventilator asynchrony during noninvasive pressure support ventilation and neurally adjusted ventilatory assist in infants and children. Pediatr Crit Care Med. 2013 Oct;14(8):e357-64. doi: 10.1097/PCC.0b013e3182917922. PubMed 23863816 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2023 to primary completion in May 2025, 17 months.

Primary completion moved twice since we started tracking on Sep 25, 2026: Mar 2027 → May 2025, last on Nov 13, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Mar 2027 → May 2025, last on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 26, 2023
StartActual
Dec 18, 2023
Primary completionActual
May 25, 2025was Mar 2027
CompletionActual
May 25, 2025was Mar 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended→Terminated Challenges associated with accrual of the eligible patient population.
changed Oct 5, 2026 · changed Nov 13, 2026
Primary completion
Mar 2027→May 25, 2025 (actual)
moved 2 times, Oct 5, 2026 – Nov 13, 2026
Study completion
Mar 2027→May 25, 2025 (actual)
moved 2 times, Oct 5, 2026 – Nov 13, 2026
Enrollment
130 (estimated)→20 (actual)
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Suspended→Terminated
    Why stopped Challenges associated with accrual of the eligible patient population.
    Primary completion Dec 2026→May 25, 2025 (now actual)
    Study completion Dec 2026→May 25, 2025 (now actual)
    Enrollment 130 (estimated)→20 (actual)
    + 1 other change: verification date
  2. Oct 5, 2026
    Recruiting→Suspended
    Why stopped Study suspended pending outcome of discussions among IRB, PI, and DSMC
    Primary completion Mar 2027→Dec 2026
    Study completion Mar 2027→Dec 2026
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06053684
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Dec 18, 2023
Primary completion
May 25, 2025
Completion
May 25, 2025
Last update
Nov 13, 2026

Study contacts

Jacqueline Weingarten, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion